Formulated with 0.9% benzyl alcohol as a preservative, it is designed to maintain sterility and support repeated withdrawals within controlled laboratory settings
Cortex 25 , 24402455 (2015)
This guide delivers a comprehensive analysis of GHK-Cus gene-modulating power, moving beyond anecdotal claims to explore its documented epigenetic impact
Medically reviewed by Oghenefejiro Okifo | MD , Harvard Medical School | Henry Ford Hospital - Detroit, MI on April 20th, 2026
What Needs to Be in Place Before a First-in-Human Trial Begins Before entering a First-in-Human trial, a drug candidate must be supported by a comprehensive package of scientific, non-clinical and quality evidence
Not approved for human or veterinary use